Live: Can Doximity’s Q4 Earnings Tonight Spark a Rebound for the Beaten-Down Stock?

That wraps up our initial coverage of Doximity’s Q4 results. Thank you for stopping by!

Check out management’s earnings call at 5 PM EST for more updates.

DOCS’s Post-Earnings Thesis Check

With Doximity (NYSE:DOCS) down nearly 17% after earnings, here’s the refreshed setup ahead of tonight’s earnings call at 5:00 PM ET.

Bull Case

• Record 800,000+ active prescribers, with nearly 50% on Clinical AI and prompts per user nearly doubling Jan-April.
• FY26 free cash flow of $317.5M funded $431.7M in buybacks at depressed prices.
• Average analyst price target of $37.77 implies meaningful upside.

Bear Case

• FY27 revenue guide of $664 million–$676 million missing consensus of $697.45 million.
• Stock-based comp doubled to $36.74M, crushing GAAP net income 69.4% YoY.
• EBITDA margin guided lower, ending a four-consecutive-quarter EPS beat streak.
• Insiders sold between $21.09 and $26.06 with no open-market buying.

Doximity (NYSE:DOCS) set its initial FY27 revenue range at $664 million–$676 million, missing consensus of $697.45 million by a wide margin. Q1 FY27 was guided to $151 million–$152 million against the Street’s $153.25 million, and FY27 adjusted EBITDA was pegged at $323 million–$335 million, a notable step down from FY26’s $355.5 million–$356.5 million exit range.

The surprise: management lowered the bar rather than reset conservatively. Key assumptions baked in include continued AI infrastructure spend, a ~5% healthcare digital ad market, and zero AI revenue contribution.

CEO Jeff Tangney still expects Doximity to “exit the year as a double-digit grower”, but the implied first-half slowdown is the bombshell driving shares down roughly 10% after hours.

Doximity (NYSE:DOCS) is down 11.57% intraday to $23.39, extending a 56.67% one-year decline.

FY27 revenue guidance of $664 million–$676 million sits well below the $697.45 million consensus, and Q1 guidance also came in light. That overshadows a Q4 revenue beat and 13% full-year growth.

Historically, DOCS has sold off on every recent report, averaging -6.6% on earnings day despite beats, with a -16.78% drop last quarter on the same growth-deceleration concern.

The market is focused on the top-line trajectory, not profitability. With analysts targeting $37.77, watch for estimate cuts tomorrow.

Doximity just reported earnings. Here are the key numbers:

• Revenue: $145.4 million vs. $143.91 million expected
• Adjusted EPS: $0.26 vs. $0.28 expected
• Adjusted EBITDA: $65.8 million
• Adjusted EBITDA Margin: 45.3%
• Free Cash Flow: $107.3 million, up 11% YoY

Guidance

• Q1 FY27 Revenue: $151 million–$152 million vs. $153.25 million expected
• FY27 Revenue: $664 million–$676 million vs. $697.45 million expected
• FY27 Adjusted EBITDA: $323 million–$335 million

Quick Read

Doximity delivered a revenue beat and continued posting strong profitability, but weaker-than-expected FY27 guidance is overshadowing the quarter and pressuring shares lower.

AI engagement metrics remained a bright spot, with more than 800,000 active prescribers using workflow tools in Q4 and nearly half of active providers now using the company’s clinical AI products.

CEO Jeff Tangney said prompts per user inside the Clinical AI Suite “nearly doubled from January to April alone,” signaling accelerating engagement across the platform.

Fiscal 2026 revenue grew 13% year over year to a record $644.9 million, while both operating cash flow and free cash flow rose 19% for the full year.

Shares are initially down roughly 10% following the report as investors focus on the softer FY27 outlook.

What Wall Street Wants to Hear on the FY27 Setup

Sell-side consensus has Doximity’s FY27 revenue bar at roughly $715M-$725M, implying low-double-digit growth after this year’s deceleration to 9.8% YoY.

CEO Jeff Tangney typically opens with a conservative initial range, then raises every quarter, which is what played out from $619M-$631M in May 2025 to $642.5M-$643.5M by February.

Investors want four things quantified:

• AI product revenue contribution beyond the 300,000+ user count
• Workflow ARPU trajectory off 720,000 prescribers
• FY27 adjusted EBITDA dollars (a flat guide signals margin reset)
• Q1 FY27 revenue

Bullish: initial FY27 above consensus with margins reiterated at 60%+.

Bearish: A wide, low-anchored range that leaves room to under-promise again.

Guidance Is Everything Tonight

Tonight’s Q4 results from Doximity (NYSE:DOCS) will likely matter less than the company’s FY2027 outlook.

Management has guided conservatively all year, raising the FY26 bar at Q1 and Q2 before narrowing to $642.5M–$643.5M in February, when the soft Q4 guide of $143M–$144M sent shares sharply lower.

Bullish: FY27 revenue above ~$720M, margins held at 55%+, Q1 above ~$160M.

Bearish: Sub-double-digit growth, margin compression from +54% R&D spend, and another light Q1 report.

With shares down 56.67% over a year and about 12% today, positive guidance could drive a rebound for the stock.

Doximity (NYSE:DOCS) is trading at $23.76 intraday, down 10.19% from yesterday’s $26.45 close as sellers position ahead of the report. Shares sit just below the 50-day moving average of $24.33 and well below the 200-day moving average at $46.51, confirming a firmly bearish intermediate trend.

Key support rests at the 52-week low of $20.55; a break opens air beneath. Resistance stacks at the 50-day, then $26.45. Despite today’s 10% slide, DOCS is still up 25.65% over one month off the April bottom, signaling fresh accumulation that could amplify a post-report move. Historical reactions have averaged -6.6% on earnings day, so volatility is the base case.

With Doximity (NYSE:DOCS) reporting Q4 earnings after the close, here’s the Bull vs Bear case for the company:

Bull Case

• AI traction is real: AI products surpassed 300,000 users in Q3 FY26, with the AI suite up 5x year-over-year in Q1.
• Best-in-class profitability: Adjusted EBITDA margin hit 60.2% in Q3, and DOCS has beaten EPS in all four prior quarters.
• Capital returns: A fresh $500M buyback with shares near 52-week lows of $20.55.

Bear Case

• Growth deceleration: Revenue growth slowed to 9.8% YoY in Q3.
• Margin compression: Net income fell 18.14% YoY as R&D surged 54%.
• Leadership overhang: CFO Anna Bryson resigned April 28, leaving an interim seat.
• AI competition: Anthropic Managed Agents threaten workflow pricing power.

Analysts’ consensus price target currently sits at $37.77, well above today’s $23.76.

Despite beating estimates in each of the past four quarters, Doximity stock has still fallen 56.67% over the past year as concerns around slowing growth, AI monetization, and leadership stability continue weighing on sentiment.

Investors want CEO Jeff Tangney to reaffirm the FY2026 outlook, provide more concrete details around AI-driven revenue opportunities, and stabilize concerns surrounding the CFO transition.

At this point, another earnings beat alone likely changes very little.

If management successfully resets the forward narrative and restores confidence in long-term growth, sentiment could improve quickly given how heavily the stock has already sold off.